JNJ-6143

2 stories · following the connections

Health

Johnson & Johnson Reports 75% Response Rate in 50-mg Phase 1 Prostate Cancer Cohort

By Naomi CalderOct 26, 2026, 7:14 PM UTC

Health

Johnson & Johnson Reports Early JNJ-6143 Responses in Prostate Cancer Trial

By Naomi CalderOct 24, 2026, 6:21 PM UTC